2023 in Review: A Year of Recognition, Growth, and Continuous Innovation at Cleerly

As we reach the end of 2023 and yet another remarkable year at Cleerly, it’s a great opportunity to reflect on all we’ve accomplished and begin planning for 2024. At Cleerly, we’ve always believed in pushing the boundaries of cardiovascular healthcare through digital innovation, and this year we continued to do just that. From industry events and awards to groundbreaking research and innovations, it was an exciting year!

In November, Cleerly achieved a milestone, with total scan analysis volume more than doubling in 2023 compared with 2022. The number of imaging center locations are up 50% from 2022 and referring providers are up nearly 200% in 2023 compared with 2022. These increases are a testament to our technology and its capabilities in transforming personalized cardiovascular care.

Here’s a look back on some highlights on what our Cleerly team has accomplished throughout 2023.

Q1: Connecting with CNBC for Healthy Returns & Presenting at ACC.23/WCC

Featured in CNBC Health Returns

I had the pleasure of speaking with Kerima Greene for CNBC’s Healthy Returns series to discuss the work we’re doing at Cleerly to detect heart attack risk and outsmart America’s number one killer, heart disease. The article dives into how we use AI to assess heart health, ultimately helping to cut down on the time it takes to flag cardiovascular concerns.

Attended ACC.23/WCC and Presented New Clinical Evidence on AI-Enabled CCTA

The Cleerly team attended the American College of Cardiology Conference together with the World Congress of Cardiology (ACC.23/WCC) and presented compelling clinical data in 9 poster and oral abstract sessions, showcasing our efforts in providing a safe and effective approach to understanding cardiovascular disease risk and guiding personalized treatment.

Q2: Growing our Team & Top 50 in Digital Health Recognition

Expanded Our Team With New Appointment of CFO and EVP of Regulatory Affairs

We welcomed Krissy Wright as Chief Financial Officer and Sandra Statz as Executive Vice President of Regulatory Affairs to our Cleerly team. These two esteemed leaders and the backgrounds they bring have allowed us to enhance our team’s expertise and presence in the health tech space.

Founder & CEO, Dr. James Min, Named a Disruptor in Rock Health’s Top 50 in Digital Health

I was named a Top 50 in Digital Health Disruptors honoree by Rock Health in their annual selection of leaders shaping the future of digital health and who represent builders, designers, innovators, and more. The disruptor category recognizes leaders whose innovative solutions are disrupting healthcare through systemic change. I’m grateful to have been included on this list and to have attended Rock Health’s Digital Health CEO Summit in San Francisco earlier in the year!

Q3: Winning & Supporting Industry Awards

Cleerly Wins “Best Overall AI Solution” in AI Breakthrough Awards

We were named “Best Overall AI Solution” by AI Breakthrough in their 2023 Awards program! These awards honor excellence and recognize innovation, hard work, and success in a range of AI and machine learning related categories. This year’s program attracted more than 3,200 nominations from over 20 countries around the world.

Attended SCCT & Supported the SCCT Clinical Trials and Registries Research Award

Our team attended and sponsored the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Boston where our executives participated in various sessions, including our well-attended lunch symposium, and a hands-on AI and machine learning cardiovascular CT workshop. While at the meeting, we presented the inaugural SCCT Clinical Trials and Registries Research Award, recognizing and supporting clinical trials that use CCTA and/or CCTA-based analyses to detect atherosclerotic burden in the diagnosis and treatment of coronary artery disease.

Q4: AI Awards, HLTH 2023 & TRANSFORM at AHA 2023

CEO and Founder, Dr. James Min Named to Business Insider AI 100 List

Business Insider acknowledged our contributions to the AI health tech sector in their inaugural AI 100 list. I’m humbled to have been featured alongside such innovative leaders. This recognition is a testament to our team’s hard work and dedication as we consistently strive to have a positive, lasting impact on the healthcare industry.

Panel Participation at HLTH 2023

It was a privilege to attend HLTH again this year in Las Vegas and to have the opportunity to participate as a panelist in the “Heart Disease, Too Long at the Top” discussion with Mariell Jessup, MD from the American Heart Association, Maayan Cohen from Hello Heart, and Wayne J. Franklin MD from Phoenix Children’s Hospital. We discussed factors that contribute to heart disease continuing to be the leading cause of death, and I described Cleerly’s commitment to creating a heart attack-free world.

Named the “Best Use of AI in Health Tech” Winner of Digital Health Hub Foundation Awards

While onsite at HLTH, our team had the honor of accepting Cleerly’s “Best Use of AI in Health Tech” Award in the Best in Class category of the Digital Health Hub Foundation Digital Health Awards, selected from over 1,500 companies worldwide. I was joined by Chief Scientific Officer, Udo Hoffmann, MD, MPH, Chief Financial Officer, Krissy Wright, and our sales leaders, Keith Irby, Barry Klegerman, and Miguel Garcia.

Attended AHA23 and Announced the TRANSFORM Trial

We joined the American Heart Association (AHA) Center for Health Technology & Innovation’s Innovators’ Network and look forward to future collaboration within the Network of so many esteemed organizations in the heart health space. Attending the AHA Scientific Sessions in Philadelphia this year was energizing as we announced the launch of the TRANSFORM trial with our partners, which is a landmark study to evaluate personalized care strategies for heart disease prevention. Additionally, I had the opportunity to participate in 2 panels with leaders in clinical science, research, and technology from all over the world.

As we look ahead to 2024, I know I can speak for myself and our entire team at Cleerly in saying we are invigorated by our achievements over the past year and we remain steadfastly committed to our mission. We aim to continue innovating and driving a new standard of care in precision heart disease prevention. I am incredibly proud of the Cleerly team and grateful to all of our partners for their ongoing support.

For more information on our efforts, research and partnerships this year, check out our latest blogs and press releases and follow our journey via LinkedIn, Facebook, Instagram and Twitter.

Thank you for being a part of our journey to create a world that is heart attack-free, and here’s to a healthier world and a transformative 2024!